Research group Xu Dawei

Our group’s major research focuses include: Epidemiology, molecular biology and certain immunological mechanisms of hematological malignancies; the biological role of lipoxygenases; and, cellular/molecular aspects of carcinogenesis and aging.

Hematological and solid tumors

Hematology Laboratory group belongs to the Division of Clinical Medicine and is located at BioClinicum, Cancer Theme. 

In the group, we focus our research on the following aspects:   

  1. Epidemiology, molecular biology and certain immunological mechanisms of hematological malignancie.;   
  2. The biological role of lipoxygenases, a family of enzymes which catalyzes the formation of active lipid mediators. The studies focus on the expression of lipoxygenases as a diagnostic tool and biological function in lymphoma.
  3. Cellular/molecular aspects of carcinogenesis and aging. Here we emphasize the role of telomerase and telomere in cancer development and aging process. Telomerase is an enzyme elongating telomere at chromosome ends, and both telomerase and telomere are important players in cancer and aging.

Our study projects above have both biological and clinical implications, and the obtained results will contribute to precision medicine.

Ongoing research

  • Telomerase activation and association with the ETS family transcription factor GABPA in cancer.
  • The direct and indirect role of telomerase reverse transcriptase (TERT) in inhibition of virus infection.

Group members

Xu Dawei

Principal researcher/Research group leader
K2 Department of Medicine, Solna


We collaborate with other researchers at Karolinsk Institutet and other universities. Within KI, we collabrate with professor Catharina Larsson.

Internationally, our collaborators include: professors Chengyun Zheng and Yidong Fan at Shandong University, China..

Research funding

  • Vetenskapsrådet
  • Cancerfonden
  • Cancerföreningen

Selected publications

Synergistic effects of telomerase reverse transcriptase and regulator of telomere elongation helicase 1 on aggressiveness and outcomes in adrenocortical carcinoma.
Yuan H, Wu Y, Wang J, Qin X, Huang Y, Yan L, Fana Y, Zedenius J, Juhlin CC, Larsson C, Lui WO, Xu D
Biomed Pharmacother 2022 May;149():112796

GABPA is a master regulator of luminal identity and restrains aggressive diseases in bladder cancer.
Guo Y, Yuan X, Li K, Dai M, Zhang L, Wu Y, Sun C, Chen Y, Cheng G, Liu C, Strååt K, Kong F, Zhao S, Bjorkhölm M, Xu D
Cell Death Differ 2020 06;27(6):1862-1877

GABPA inhibits invasion/metastasis in papillary thyroid carcinoma by regulating DICER1 expression.
Yuan X, Mu N, Wang N, Strååt K, Sofiadis A, Guo Y, Stenman A, Li K, Cheng G, Zhang L, Kong F, Ekblad L, Wennerberg J, Nilsson IL, Juhlin CC, Larsson C, Xu D
Oncogene 2019 02;38(7):965-979

Telomerase reverse transcriptase regulates DNMT3B expression/aberrant DNA methylation phenotype and AKT activation in hepatocellular carcinoma.
Yu J, Yuan X, Sjöholm L, Liu T, Kong F, Ekström TJ, Björkholm M, Xu D
Cancer Lett 2018 10;434():33-41

Intrinsic 5-lipoxygenase activity regulates migration and adherence of mantle cell lymphoma cells.
Xia C, Sadeghi L, Strååt K, Merrien M, Wright AP, Sander B, Xu D, Österborg A, Björkholm M, Claesson HE
Prostaglandins Other Lipid Mediat 2021 10;156():106575

Hodgkin Lymphoma Monozygotic Triplets Reveal Divergences in DNA Methylation Signatures.
Xia C, Olsen TK, Zirakzadeh AA, Almamoun R, Sjöholm LK, Dahlström J, Sjöberg J, Claesson HE, Johnsen JI, Winqvist O, Xu D, Ekström TJ, Björkholm M, Strååt K
Front Oncol 2020 ;10():598872

Expansion of immunoglobulin autoreactive T-helper cells in multiple myeloma.
Ostad M, Andersson M, Gruber A, Sundblad A
Blood 2008 Mar;111(5):2725-32

Transformation of mature mouse B cells into malignant plasma cells in vitro via introduction of defined genetic elements.
Högstrand K, Lindvall JM, Sundblad A, Grandien A
Eur J Immunol 2019 03;49(3):454-461

Trends in survival of young adult patients with acute lymphoblastic leukemia in Sweden and the United States.
Björkholm M, Edgren G, Dickman PW
Blood 2019 07;134(4):407-410

Reproductive history, as measured by parity, age at first birth and sex of offspring, and cancer-specific survival after a haematological malignancy.
Johansson ALV, Dickman PW, Eloranta S, Björkholm M
Acta Oncol 2022 Apr;():1-9

Content reviewer: